PDF factsheet

poly ADP-ribose polymerase (PARP) inhibitor in ovarian cancer for patients with BRCA mutation, clinical trials results

niraparib versus placebo
ENGOT-OV16/NOVA gBRCA, 2017 NCT01847274	niraparib (300 mg) once daily as maintenance treatment versus placebo	patients with platinum-sensitive, recurrent ovarian cancer with germline BRCA mutation	double-blind
olaparib versus placebo
SOLO2/ENGOT-Ov21, NCT01874353	olaparib 300 mg in two 150 mg tablets, twice daily versus placebo	patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation	double-blind international

Group by
in first

in second

Order trials by

display ongoing trials

Type of trial

Limit to tags

Exclude tags